Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
ConclusionThe impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs
This article summarises a symposium at the XIX World Congress of the International Union of Phlebology held in Istanbul, Turkey, in September 2022. Common pathophysiological features of CVD and cardiovascular disease are endothelial injury, hypercoagulability and systemic inflammation. In CVD, inflammation primarily affects the microcirculation, with changes in capillary permeability, vein wall and valve remodelling and increase in oxidative stress. Once patients develop symptoms/signs of CVD, they tend to reduce their physical activity, which may contribute to increased risk of cardiovascular disease. Data show that the p...
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
ConclusionThe results suggest that SPC R10/E10 improve LDL-C reduction and goal achievement in Chinese patients with primary hypercholesterolemia not adequately controlled on statin therapy, without new safety findings.Trial RegistrationClinicalTrials.gov (NCT04669041). (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary
ConclusionTo our knowledge, this is the first study to assess treatment patterns in patients with mUC in clinical practice in Hungary, using the national health insurance database. Rates of first- and second-line treatment were consistent with those observed in other countries. Avelumab first-line maintenance treatment became available for reimbursement in Hungary in late 2022, after the study period. Given the evolving landscape of reimbursed treatments in Hungary, further analyses are warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Symptom and Treatment Satisfaction in Members of the US and Canadian GBS/CIDP Foundations with a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy
ConclusionsA high proportion of members of the US and Canadian GBS/CIDP Foundations reporting a diagnosis of CIDP were unsatisfied with current symptoms, despite a high level of overall satisfaction with treatments. There is an unmet need for improving long-term outcomes in people with a diagnosis of CIDP, and for studying patient-centered long-term treatment goals. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
ConclusionThis real-world study demonstrates the effect of cladribine tablets over 12 months on PROs of fatigue, physical function, treatment satisfaction, and work productivity.Trial RegistrationThe CLAWIR study is registered at the German Federal Institute for Drugs and Medical Devices with the internal NIS number 7469. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies
AbstractComplement 3 glomerulopathy (C3G) is an ultra-rare, progressive kidney disease resulting from dysregulation of the alternative complement pathway. Clinical presentation of C3G is heterogeneous and definitive diagnosis relies on kidney biopsy and immunofluorescence staining. The term C3G encompasses two subgroups, dense deposit disease and C3 glomerulonephritis, distinguished via electron microscopy. In this podcast article, the authors discuss the challenges associated with C3G diagnosis and the central role of kidney biopsy. Using an illustrative case study, key histological observations are described, and best pr...
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis
ConclusionFaricimab provides a new treatment option in DME with dual-pathway inhibition of VEGF and angiopoeitin-2 (Ang-2). To the authors ’ knowledge, this is the first indirect comparison of faricimab T&E in DME. The analyses indicate that faricimab T&E is associated with superior retinal drying along with numerically fewer injections compared to all other treatments given in flexible dosing regimens. It also showed superior visual acuity outcomes compared to ranibizumab and bevacizumab. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Factors Contributing to the Change in Overweight/Obesity Prevalence Among Indian Adults: A multivariate decomposition analysis of data from the National Family Health Surveys
ConclusionsThe incremental rise in such a short period, mainly attributed to the effect of socio-demographic variables, is concerning. Policy interventions should prioritize health advocacy programs and aggressively target behavioral modifications while preparing the health systems to manage the people living with obesity. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Development of a Conceptual Model for the Patient Experience of Focal Segmental Glomerulosclerosis (FSGS): A Qualitative Targeted Literature Review
ConclusionSecondary analysis of published qualitative literature permitted development of a CM describing the adult and pediatric experience of FSGS. Concept elicitation interviews are recommended to refine the CM, confirm the salient/most bothersome concepts, and confirm the extent of impact on daily life. The refined CM will provide a useful tool to inform the selection, development, and/or amendment of COAs for use in future FSGS clinical trials. (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
ConclusionThough ISRs were common, most were mild, and the percentage of patients reporting ISRs declined from PEGASUS through the 307 OLE. Patient compliance remained high, and no patients discontinued because of ISRs, suggesting that ISRs do not pose a barrier to long-term pegcetacoplan treatment.Trial registrationClinicalTrials.gov identifiers: NCT03500549 (PEGASUS) and NCT03531255 (307 OLE). (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
ConclusionRelugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.Trial RegistrationClinical Trial ID NCT03085095.Prior Presentation Data presented at 15th Annual Genitourinary Cancers Symposium; February 17 –19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found athttps://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer
ConclusionFrom the perspective of the Chinese healthcare system, this study ’s findings suggested that first-line TC represents a cost-effective strategy for patients with advanced NSCLC. However, the cost-effectiveness of first-line TC varied across different subgroups when considering predictive biomarkers. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Xioglican Cream in Italian Patients with Chronic Venous Disease: A Post-Marketing Study Investigating Effects on Clinical and Cutaneous Signs and Symptoms
ConclusionsTopical treatment with Xioglican cream improves the signs, symptoms, and QoL of patients with CVD class C2 –C3. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Factors Associated with Topical Medication Instillation Failure in Glaucoma: VRAMS-QPiG Study
ConclusionIn addition to older age, decreased cognitive function, hyperopia, and decreased foveal sensitivity are risks for failed eyedrop instillation. Treating physicians can screen patients who require guidance by checking the risk factors of instillation failure rather than by relying on patient reports. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
